Technical Data Sheet

Purified Rat Anti-Human IL-2

Product Information

 Material Number:
 554563

 Size:
 0.1 mg

 Concentration:
 0.5 mg/ml

 Clone:
 MQ1-17H12


Immunogen: Human IL-2 Recombinant Protein


 $\begin{array}{lll} \textbf{Isotype:} & \text{Rat IgG2a, } \kappa \\ \textbf{Reactivity:} & \text{QC Testing: Human} \end{array}$


Storage Buffer: Aqueous buffered solution containing $\leq 0.09\%$ sodium azide.

Description

The MQ1-17H12 antibody reacts with human interleukin-2 (IL-2). The immunogen used to generate the MQ1-17H12 hybridoma was recombinant human IL-2. Unconjugated or purified forms of this antibody have been reported to be neutralizing for human IL-2 bioactivity.







Expression of IL-2 by stimulated CD3+ human PBMC. Human PBMCs were stimulated for 6 hours with PMA (50 ng/ml final concentration; Sigma, Cat. #P-8139) and calcium ionophore A23187 (500-100 ng/ml final concentration; Sigma, Cat. #C-9275) in the presence of BD GolgiStop™ (2 μM final concentration; Cat. No. 554724). The PBMCs were stained with PE-Cy™5-anti-CD3 (PE-Cy™5-UCHT1, Cat. No. 555334), fixed, permeabilized, and then stained with 0.25 μg of FITC-rat anti-human IL-2 antibody (FITC-MQ1-17H12, Cat. No. 554565) using Pharmingen's staining protocol (left panel). To demonstrate specificity of staining, the binding of FITC-MQ1-17H12 was blocked by the preincubation of the fluorochrome - conjugated antibody with recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603; middle panel), and by preincubation of the fixed/permeabilized cells with unlabeled MQ1-17H12 antibody (5.0 μg, Cat. No. 554563; right panel) prior to staining with the FITC-MQ1-17H12 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody blocking (right panel) specificity controls.

Preparation and Storage

Store undiluted at 4°C.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Application Notes

Application

PP	
ELISA Capture	Routinely Tested
Intracellular block/flow cytometry	Tested During Development
Immunocytochemistry (cytospins)	Tested During Development

Recommended Assay Procedure:

Blocking Control for Intracellular Staining: The purified MQ1-17H12 antibody (Cat. No. 554563) can be used as a blocking control to demonstrate specificity of IL-2 staining of directly conjugated MQ1-17H12 antibody. To perform this control, the fixed/permeabilized cells (\sim 1 million) can be incubated with 1 -10 μ g of unlabeled MQ1-17H12 antibody (Cat. No. 554563) for 20 minutes at 4°C, prior to staining with conjugated antibody (e.g., 0.1 -0.5 μ g mAb/1X10^6 cells). The intracellular cytokine staining technique and use of blocking controls are described in detail by C. Prussin and D. Metcalfe. For specific methodology, please visit the protocol section on our web site, http://www.bdbiosciences.com/resources/index.jsp

Neutralization/Blocking: THE NA/LETM format of the MQ1-17H12 antibody (Cat. 554562) is useful for neutralization of human IL-2 bioactivity. A suitable NA/LETM isotype control to match the NA/LETM MQ1-17H12 antibody is the R35-95 antibody (Cat. No. 554687).

BD Biosciences

bdbiosciences.com

 United States
 Canada
 Europe
 Japan
 Asia Pacific
 Latin America/Caribbean

 877.232.8995
 800.979.9408
 32.53.720.550
 0120.8555.90
 65.6861.0633
 55.11.5185.9995

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be constructed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be help responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is stictly prohibited. For Research Use Only, Not for use in diagnostic or therapeutic procedures. Not for resale.

Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2011 BD



554563 Rev. 5 Page 1 of 2

ELISA Capture: The purified MQ1-17H12 antibody is useful as a capture antibody for a sandwich ELISA for specifically measuring human IL-2 protein levels. The biotinylated B33-2 antibody (Cat. No. 555040) can be paired with the purified MQ1-17H12 antibody (Cat. No. 554563) as the capture antibody, with recombinant human IL-2 (Cat. No. 554603) as the standard. For specific methodology, please visit the protocols section on our website, http://www.bdbiosciences.com/resources/index.jsp

Suggested Companion Products

Catalog Number	Name	Size	Clone	
554724	Protein Transport Inhibitor (Containing Monensin)	0.7 ml	(none)	
555334	PE-Cy [™] 5 Mouse Anti-Human CD3	100 tests	UCHT1	
554565	FITC Rat Anti-Human IL-2	0.1 mg	MQ1-17H12	
554603	Recombinant Human IL-2	10 μg	(none)	
554715	BD Cytofix/Cytoperm Plus Kit (with BD GolgiStop)	250 tests	(none)	

Product Notices

- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- 2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- 3. This product is manufactured and sold under license from Pestka Biomedical Laboratories, Inc. (d/b/a PBL InterferonSource) and may be used solely as indicated. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics is strictly prohibited. This product is covered by U.S. Patent No. 5,597,901 and Bulgarian Patent No. BG1895.
- 4. Cy is a trademark of Amersham Biosciences Limited.
- 5. All other brands are trademarks of their respective owners.
- 6. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.

References

Andersson J, Abrams J, Bjork L, et al. Concomitant in vivo production of 19 different cytokines in human tonsils. *Immunology.* 1994; 83(1):16-24. (Biology) Fernandez V, Andersson J, Andersson U, Troye-Blomberg M. Cytokine synthesis analyzed at the single-cell level before and after revaccination with tetanus toxoid. *Eur J Immunol.* 1994; 24(8):1808-1815. (Biology)

Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. *J Immunol Methods*. 1995; 188(1):117-128. (Methodology: IC/FCM Block)

BD Biosciences

bdbiosciences.com

 United States
 Canada
 Europe
 Japan
 Asia Pacific
 Latin America/Caribbean

 877.232.8995
 800.979.9408
 32.53.720.550
 0120.8555.90
 65.6861.0633
 55.11.5185.9995

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be constructed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be help responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is stictly prohibited. For Research Use Only, Not for use in diagnostic or therapeutic procedures. Not for resale.

Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2011 BD



554563 Rev. 5 Page 2 of 2